Boothbay Fund Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Boothbay Fund Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-18,414	Closed	-$108K	–	2670
2022 Q4	$108K	Buy	+18,414	New	+$96.8K	﹤0.01%	1765
2021 Q1	–	Sell	-10,000	Closed	-$126K	–	1875
2020 Q4	$126K	Buy	+10,000	New	+$114K	﹤0.01%	1161

Boothbay Fund Management's CNCE Position: Q1 2023 in Review

Boothbay Fund Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 18,414 shares — an estimated $108K sold.

Boothbay Fund Management first reported a position in CNCE in Q4 2020 and held it in 2 quarters. The position peaked at $126K in Q4 2020. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

Boothbay Fund Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Boothbay Fund Management sold 18,414 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $108K.
Boothbay Fund Management first reported a position in Concert Pharmaceuticals, Inc. in Q4 2020 and held it in 2 quarters.
Boothbay Fund Management's Concert Pharmaceuticals, Inc. position peaked at $126K in Q4 2020.
0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on Boothbay Fund Management's 13F filing for Q1 2023, filed 15 May 2023.